October 11, 2012 /24-7PressRelease/
-- Pressure BioSciences
, Inc., a life sciences company, engages in the development and commercialization of pressure cycling technology
(PCT). PBIO comparisions that are leaders in the industry are Thermo Fisher Scientific, Inc. (NYSE:TMO) and (NYSE:A) Agilent Technologies Inc.
The sample preparation market is expected to grow to $8.4 billion by 2016. Pressure BioSciences, Inc. (OTC.BB: PBIO), a diversified technology company out of Massachusetts, is spearheading this aspiring subdivision of the life sciences market. With their Barocyclers, Microtubes and Isolation Kits that put molecules into workable states, protected by 24 issued patents, PBIO is grabbing the proverbial reigns in 2012.
In the last year alone, the company was awarded $910,000 in grants from the National Institute of Health and Department of Defense to put the final touches on sharpening their proprietary Pressure Cycling Technology
or "PCT." This contribution went towards work with the US Army and it program to protect the war fighter by developing a state-of-the-art system that can kill anthrax and other "bad bugs" that might be used in a bioterror attack. PBIO's PCT technology completely kills anthrax and other bad bugs that might be present in a suspicious sample being tested from the war zone or elsewhere, thus eliminating the risk of infecting the person performing the test. And, that's only the tip of the iceberg. With more than a dozen commercially-viable applications spanning the academic, government and biotech sectors, PBIO has a virtual monopoly on controlling molecular behavior through pressure.
Now, PBIO's intense R & D focus on proteomic, genomic and small molecules is paying dividends in the important areas of efficacy, and more importantly, time. With PCT, laboratory results are often achieved within 20 to 40 minutes while old methods keep scientists waiting on evidence for up to 20 hours. Researchers at Florida International University and the University of North Texas confirmed this expedition. The speed, in particular, is especially valuable for pharmaceutical and biotech companies that want to corner markets with more immediate cures. After all, clinical studies tend to drag on enough as it is.
Pressure BioSciences, Inc. has 24 issued patents (14 in the U.S. and 10 foreign). It has only 10 million shares outstanding, which is very little for a development stage biotech company. After dipping as low as $0.20 per share and peaking at $7.00, the price of PBIO stock has settled around $0.29 - a number that PBIO executives, and research analysts from ViewTrade Securities
and Zacks Financial, believe highly undervalues the products as well as the company as a whole.
However, the company has only been a stand-alone company for about six years, and only now is it shifting its attention from research to sales. PBIO had sales of about $1 million a year for the last three years, but the vast majority of its efforts over this time were mostly focused on development - honing and sharpening the unique PCT instruments and consumables so that world-class laboratories could use them, study them closely and write academic papers thereby spreading the word. So far, the company has sold more than 200 PCT instrument systems to more than 150 labs in the U.S. and abroad (Amgen (AMGN) and Thermo Fisher Scientific (TMO) to name a couple.
The Competition? Slim to none. PBIO is the only company with such PCT capability thus far.
In an interview with Harry Norman of Proactive Investors, Pressure BioSciences' CEO Richard Schumacher said, "We bring high pressure into the lab. It's never been done before. The pressures that we bring into the lab are equal to two or three times the pressure you see at the bottom of the deepest part of the Pacific Ocean. Everything in nature has a pressure profile. In addition, we are the first company worldwide to have the means to bring such pressure pressure very safely, very controllably, into the laboratory setting. With an estimated 500,000 scientists who can benefit from using pressure, we are very excited to begin to actively sell our PCT System."
Schumacher went on to say that he believes PBIO is potentially worth more than the combined market capitalization of his previous three companies (with combined market caps at or above $1 billion). And, as we mentioned earlier, 2012 is starting to show that. PBIO's revenue for the year is already 70 percent greater than that of 2011 with sales of both instruments and consumables shooting up. Schumacher confirmed that this was their year for launching an aggressive and comprehensive commercialization plan.
This starts by adding internal salespeople and expanding their distribution network overseas. In the United States, PBIO is expanding their strategic partnerships. They even got Dr. Henry C. Lee, the world-class forensic scientist who appeared at the O.J. Simpson trial, to join the cause of investigating PCT for multiple areas of forensic analysis.
The only area in question is the future molding of PCT around new applications. In other words, a PCT instrument aimed at yielding DNA for the FBI or a forensics team may need to be tweaked for pressure cycle and heat differently than an application intended for the pharmaceutical industries or biotech sector. Then again, PBIO has come this far with a revolutionary product...tweaking PCT to fit any number of different goals should only be an issue of trial and error, at the most.
In our opinion, many investors have not realized how significantly undervalued PBIO is at current levels. The smart ones will act now - just as the company begins to tackle commercialization with the same tenacity and ingenuity it applied to taking PCT from an unknown technology five years ago to one that has the potential to change the course of scientific research today.
Always do your own research, a good place to begin is, http://www.otcmarkets.com/stock/PBIO/company-info
Always read full disclaimer disclosure pertaining to this article http://tomorrowsbluechips.com/disclaimer/
922 Mc Mulllen Booth Rd
Clearwater FL 33759
Source . Seraphim Strategies Clearwater FL
Forward Looking Statements
Statements contained in this press release regarding the Company's intentions, hopes, beliefs, expectations, or predictions of the future are "forward-looking'' statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward looking statements include the estimated size of the life sciences sample preparation market; the Company's plans and ability to secure sufficient financing to support working capital needs, including its expanded and more aggressive commercialization program; that data presented by nationally-recognized experts indicated that the PCT System offered significant advantages in sexual assault sample processing and in drug discovery applications; and that measurable progress was made in the development of the Company's automated, portable, high throughput PCT System and in a second PCT System intended to improve processing of cancer and other samples. These statements are based upon the Company's current expectations, forecasts, and assumptions that are subject to risks, uncertainties, and other factors that could cause actual outcomes and results to differ materially from those indicated by these forward-looking statements. These risks, uncertainties, and other factors include, but are not limited to: the Company's financial results for the quarter ended March 31, 2012 may not necessarily be indicative of future results as future revenues may not meet expectations due to the possible failure of the Company's products to achieve commercial acceptance, changes in customer's needs and technological innovations, expenses that may be higher than anticipated due to unforeseen costs or cost increases, and the Company may not secure sufficient capital to fully implement its plans; possible difficulties or delays in the implementation of the Company's strategies that may adversely affect the Company's continued commercialization of PCT; and the Company may not be successful in selling its PCT product line because scientists may not perceive the advantages of PCT over other sample preparation methods. Further, the Company will require additional working capital to fund its operations beyond the end of May 2012, and there can be no assurance that the Company will be successful in obtaining such financing on acceptable terms, if at all. Additional risks and uncertainties that could cause actual results to differ materially from those indicated by these forward-looking statements are discussed under the heading "Risk Factors" in the Company's Annual Report on Form 10-K for the year ended December 31, 2011, and other reports filed by the Company from time to time with the SEC. The Company undertakes no obligation to update any of the information included in this release, except as otherwise required by law.